Arrhythmias & electrophysiology
Left Atrial Appendage Occlusion in Patients With Atrial Fibrillation and Cancer
Authors' conclusion
Within our cohort, LAAO in cancer patients was achieved with good procedural success and offered a reduction in stroke at no increased bleeding risk similar to noncancer patients.
Study context
- Population
- Patients with nonvalvular atrial fibrillation (AF) who underwent left atrial appendage occlusion (LAAO) at Mayo Clinic sites, 2017–2020
- Participants
- 55 cancer patients
- Exposure
- LAAO in cancer patients vs LAAO in patients without cancer
- Outcome
- Ischemic stroke and death, cancer vs non-cancer LAAO controls
- Follow-up
- First year
Methodological detailsMayo Clinic sites
- Mayo Clinic sites
Main finding
As reported in the abstract
first year
Cancer vs ControlsHazard ratio (95% CI)P value
Ischemic stroke
0.44(0.10–1.97)
P = 0.28Death
1.39(0.73–2.64)
P = 0.32- Ischemic stroke over first year, cancer patients
- 1 (1.4%)
- Death over first year, cancer patients
- 3 (6.5%)
Observational data: associations, not effects.
Safety
| Outcome | HR (95% CI) | P value | |
|---|---|---|---|
| Bleeding complications · first year | 0.71 (0.28–1.86) | P = 0.19 | |
| 0.20.5125Hazard ratio (log scale) |
- Bleeding complications — Bleeding complications over first year, cancer patients
- 5 (10.7%)
Bleeding complications · first year
- No significant difference vs controls
Original publication
Left Atrial Appendage Occlusion in Patients With Atrial Fibrillation and Cancer. JACC CardioOncol. Published 7 March 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →